CG Oncology Stock Soars 16.93% Despite Earnings Miss

On August 12, 2025, CG Oncology's stock surged by 16.93% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Wall Street Zen has downgraded CG Oncology from a "hold" to a "sell" rating, indicating a pessimistic outlook for the company's future performance. This shift in rating reflects growing concerns among analysts about the company's prospects.

Bank of America (BofA) has lowered its price target for CG Oncology from $63 to $62, while maintaining a "buy" rating on the shares. This adjustment comes after the company's Q2 report, which showed a widening loss of 93% and zero revenue, falling short of analyst estimates.

The absence of product sales ahead of commercialization has raised questions about the company's ability to generate revenue in the near term, contributing to the negative sentiment surrounding the stock.